Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 4/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099826 | 0.94 | KCNH2 (0.46) | NOS1NOS3NOS2BACE1KCNH2 | |
| SCHEMBL30391820 | 0.88 | NOS2 (0.47) | NOS1NOS3NOS2BACE1KCNH2 | |
| SCHEMBL6454774 | 0.88 | NOS2 (0.47) | NOS1NOS3NOS2BACE1KCNH2 | |
| SCHEMBL4718869 | 0.82 | NOS1 (0.46) | NOS1NOS3NOS2BACE1KCNH2 | |
| SCHEMBL25236931 | 0.80 | KCNH2 (0.47) | NOS1NOS2KCNH2 | |
| SCHEMBL1269597 | 0.80 | KCNH2 (0.62) | NOS1NOS3NOS2BACE1KCNH2 | |
| SCHEMBL30320127 | 0.80 | KCNH2 (0.47) | NOS1NOS2KCNH2 | |
| SCHEMBL24618193 | 0.80 | KCNH2 (0.47) | NOS1NOS2KCNH2 | |
| SCHEMBL855285 | 0.79 | — | — | |
| SCHEMBL2567286 | 0.79 | KCNH2 (0.59) | NOS1NOS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3315492-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | NOS1 1418/4885NOS3 2385/4885NOS2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.